Exagen (XGN) Competitors $7.00 -0.18 (-2.51%) Closing price 04:00 PM EasternExtended Trading$7.02 +0.01 (+0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. CSTL, LFMD, CELC, OMDA, FTRE, AUNA, TALK, SBC, EHAB, and AIRSShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Castle Biosciences (CSTL), LifeMD (LFMD), Celcuity (CELC), Omada Health (OMDA), Fortrea (FTRE), Auna (AUNA), Talkspace (TALK), SBC Medical Group (SBC), Enhabit (EHAB), and AirSculpt Technologies (AIRS). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors Castle Biosciences LifeMD Celcuity Omada Health Fortrea Auna Talkspace SBC Medical Group Enhabit AirSculpt Technologies Castle Biosciences (NASDAQ:CSTL) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Which has more risk & volatility, CSTL or XGN? Castle Biosciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Do analysts prefer CSTL or XGN? Castle Biosciences currently has a consensus target price of $37.00, indicating a potential upside of 123.70%. Exagen has a consensus target price of $7.50, indicating a potential upside of 7.14%. Given Castle Biosciences' higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Exagen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in CSTL or XGN? 92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 6.5% of Castle Biosciences shares are owned by insiders. Comparatively, 12.6% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor CSTL or XGN? In the previous week, Castle Biosciences had 4 more articles in the media than Exagen. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Exagen. Castle Biosciences' average media sentiment score of 0.89 beat Exagen's score of 0.63 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CSTL or XGN more profitable? Castle Biosciences has a net margin of -1.46% compared to Exagen's net margin of -27.34%. Castle Biosciences' return on equity of 3.41% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Castle Biosciences-1.46% 3.41% 2.95% Exagen -27.34%-133.69%-34.87% Which has higher earnings and valuation, CSTL or XGN? Castle Biosciences has higher revenue and earnings than Exagen. Castle Biosciences is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCastle Biosciences$332.07M1.44$18.25M-$0.19-87.05Exagen$55.64M2.68-$15.11M-$0.84-8.33 SummaryCastle Biosciences beats Exagen on 11 of the 15 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.93M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E Ratio-8.3311.7121.0120.09Price / Sales2.6830.03433.8199.01Price / CashN/A22.3936.1658.27Price / Book12.963.578.125.65Net Income-$15.11M$235.43M$3.25B$257.91M7 Day Performance0.14%-1.67%0.97%2.09%1 Month Performance-4.89%2.91%7.36%11.13%1 Year Performance262.69%-16.44%31.31%18.40% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen3.1505 of 5 stars$7.00-2.5%$7.50+7.1%+250.2%$152.93M$55.64M-8.33220News CoverageCSTLCastle Biosciences2.2 of 5 stars$19.46-4.1%$37.00+90.1%-10.4%$586.11M$332.07M-102.42540News CoveragePositive NewsLFMDLifeMD2.5677 of 5 stars$12.20-2.4%$12.00-1.6%+64.4%$568.09M$212.45M-35.88230Positive NewsCELCCelcuity1.9651 of 5 stars$13.34-3.3%$28.40+112.9%-24.3%$522.18MN/A-4.4040OMDAOmada HealthN/A$18.67+0.2%$23.57+26.3%N/A$479.72MN/A0.00849Quiet Period ExpirationFTREFortrea3.7229 of 5 stars$4.45-14.8%$15.00+237.1%-81.6%$472.41M$2.70B-0.5115,500Gap UpAUNAAuna3.5084 of 5 stars$6.25-1.3%$10.70+71.3%-28.1%$468.50M$1.17B10.7714,842TALKTalkspace3.7513 of 5 stars$2.65-4.3%$4.50+69.8%+15.1%$463.46M$187.59M132.57500News CoveragePositive NewsSBCSBC Medical GroupN/A$4.51+0.9%N/AN/A$463.14M$205.42M0.00N/ANews CoveragePositive NewsEHABEnhabit3.4276 of 5 stars$7.31-4.4%$8.75+19.7%-31.0%$387.38M$1.03B-2.6410,700News CoverageAIRSAirSculpt Technologies1.2934 of 5 stars$5.39-0.2%$3.75-30.4%+25.1%$317.41M$180.35M-17.97240Positive News Related Companies and Tools Related Companies CSTL Alternatives LFMD Alternatives CELC Alternatives OMDA Alternatives FTRE Alternatives AUNA Alternatives TALK Alternatives SBC Alternatives EHAB Alternatives AIRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
